TCTR20210913001已完成不适用
Immunogenicity and safety of heterologous and homologous prime-boost schedules with an adenoviral vectored and inactivated SARS-CoV-2 (COVID-19) vaccines
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Thai nationality
- •2. Received one dose of CoronaVac 3-4 weeks prior or one dose of ChAdOx1-S nCoV-19 4-12 weeks prior
排除标准
- •1. Prior COVID-19 infection
- •2. Allergic to vaccine or vaccine component
- •3. Receiving immunosuppressants, immunoglobulin or blood components within 3 months
- •4. Anatomical or functional asplenia
- •5. Drug abuse or alcoholism
- •6. Autoimmune or immunodeficiency diseases
- •7. Pregnancy or lactation
研究者
相似试验
招募中
4 期
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.Covid19D012141RBR-5y9y7p7Secretaria Municipal de Saúde do Rio de Janeiro
已完成
不适用
Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-boost of Inactivated Vaccine and Replication-defective Viral Vectors Vaccine Against SARS-CoV2 among Hemodialysis Patients: An Observational Prospective Cohort TrialTCTR20220516002Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand130
已完成
不适用
Safety of Malaria vaccines in Gambian infantsPaediatricsMalariaPACTR201401000363170niversity of Oxford36
已完成
不适用
Safety of Malaria vaccines in Gambian childrePaediatricsMalariaPACTR201204000362870niversity of Oxford36
Unknown
不适用
Safety of Malaria vaccines in Gambian adults , children and infantsMalariaPACTR201008000221638Oxford University, Jenner Institute52